Associated Papers
New progress in the study of germline susceptibility genes of myeloid neoplasms.
Bi L et al.
Oncology Letters, 2021
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N et al.
Leukemia, 2017
LNK mutations and myeloproliferative disorders.
McMullin MF et al.
American Journal of Hematology, 2016
LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation.
Hurtado C et al.
Leukemia Research, 2011
[Classification for myeloproliferative neoplasms and function of novel mutations].
Kirito K
[rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 2011
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A et al.
Leukemia, 2010
LNK mutations in JAK2 mutation-negative erythrocytosis.
Lasho TL et al.
The New England Journal of Medicine, 2010
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST et al.
Blood, 2010
Select a paper to view details